NCT05636787View on ClinicalTrials.gov

Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

April 30, 2028

Conditions
Multiple Myeloma
Interventions
DRUG

Treosulfan

Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan

DRUG

Melphalan

Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan

Trial Locations (1)

3010

RECRUITING

Departement of Medical Oncology, University Hospital Berne, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER